Essentials of cardio-oncology
© Royal College of Physicians 2023. All rights reserved..
Cardio-oncology is a subspecialty that provides cardiac care for patients with cancer. Newer oncological agents have not only increased survivorship, but also sprouted novel cardiovascular toxicity (CVT) involving any component of the cardiovascular system, albeit with some preferential targets. Patients with cancer should undergo a baseline cardiovascular risk assessment and have individualised surveillance planned during cancer therapy and post treatment. The early diagnosis of CVT, by clinical history and examination along with imaging and laboratory analysis, is paramount. Management includes cardioprotective strategies and multidisciplinary decision-making regarding the risk-benefit ratio of oncological treatment based on CVT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical medicine (London, England) - 23(2023), 1 vom: 25. Jan., Seite 52-55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferreira, Vera Vaz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 27.01.2023 Date Revised 26.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.7861/clinmed.2022-0588 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352075538 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352075538 | ||
| 003 | DE-627 | ||
| 005 | 20240426233122.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7861/clinmed.2022-0588 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM352075538 | ||
| 035 | |a (NLM)36697021 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferreira, Vera Vaz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Essentials of cardio-oncology |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.01.2023 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Royal College of Physicians 2023. All rights reserved. | ||
| 520 | |a Cardio-oncology is a subspecialty that provides cardiac care for patients with cancer. Newer oncological agents have not only increased survivorship, but also sprouted novel cardiovascular toxicity (CVT) involving any component of the cardiovascular system, albeit with some preferential targets. Patients with cancer should undergo a baseline cardiovascular risk assessment and have individualised surveillance planned during cancer therapy and post treatment. The early diagnosis of CVT, by clinical history and examination along with imaging and laboratory analysis, is paramount. Management includes cardioprotective strategies and multidisciplinary decision-making regarding the risk-benefit ratio of oncological treatment based on CVT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a NEWS | |
| 650 | 4 | |a deterioration | |
| 650 | 4 | |a hypercapnia | |
| 650 | 4 | |a patient safety | |
| 650 | 4 | |a respiratory failure | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Ghosh, Arjun K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical medicine (London, England) |d 2001 |g 23(2023), 1 vom: 25. Jan., Seite 52-55 |w (DE-627)NLM112411673 |x 1473-4893 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:1 |g day:25 |g month:01 |g pages:52-55 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7861/clinmed.2022-0588 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 1 |b 25 |c 01 |h 52-55 | ||